# What are the Possible Outcomes of Thyroid Nodule Biopsy?

Thyroid nodule biopsy, also known as fine needle aspiration (FNA) biopsy, is a crucial diagnostic tool for evaluating thyroid nodules. The possible outcomes of a thyroid nodule biopsy can be categorized into several groups:

## Biopsy Results

### Benign
The majority of thyroid nodule biopsies (approximately 70%) yield benign results[^1]. This indicates that the nodule is non-cancerous and typically requires no further intervention unless it causes symptoms due to its size or growth[^3].

### Malignant
About 3% to 7% of thyroid biopsy results are classified as malignant[^1]. This diagnosis confirms the presence of thyroid cancer and usually necessitates surgical intervention.

### Suspicious
When a biopsy result is deemed suspicious, there is a 60% to 75% chance that the nodule is cancerous[^1]. These cases often require additional testing or surgical removal for definitive diagnosis.

### Atypia of Undetermined Significance (AUS)
This category indicates that the nodule has both benign and malignant characteristics. Approximately 5% to 15% of nodules in this category are ultimately found to be cancerous[^1].

### Follicular Neoplasm
For nodules classified as follicular neoplasms, it is challenging to determine malignancy without surgical removal. About 15% to 30% of these nodules are eventually diagnosed as cancerous[^1].

### Non-diagnostic
A non-diagnostic result occurs when there are insufficient cells in the sample to make a reliable diagnosis[^1]. This outcome is seen in about 7.2% of cases, and of these, approximately 13.4% are found to be cancerous when surgically removed[^5].

## Accuracy and Limitations

The overall accuracy of thyroid nodule biopsy is approximately 86%[^5]. However, it's important to note that false-negative results can occur. In some cases, a biopsy may come back as benign even though cancer is present, although this is rare[^4].

For nodules 4 cm or larger, the accuracy of FNA biopsy decreases significantly. Studies have shown that in these cases, up to 50% of nodules initially reported as benign on FNA were later found to be neoplastic or malignant upon surgical removal[^2].

## Additional Considerations

In cases where biopsy results are indeterminate or suspicious, additional testing such as molecular marker analysis may be recommended[^3]. These tests can help refine the diagnosis and guide treatment decisions.

It's crucial to remember that while thyroid nodule biopsy is a valuable diagnostic tool, its results should be interpreted in conjunction with other clinical factors, including ultrasound findings and patient risk factors, to determine the most appropriate management strategy.

---

## Citations
[^1]: [Cleveland Clinic: Thyroid Biopsy](https://my.clevelandclinic.org/health/diagnostics/thyroid-biopsy)  
[^2]: [PMC: FNA of Thyroid Nodules](https://pmc.ncbi.nlm.nih.gov/articles/PMC2910711/)  
[^3]: [Mount Sinai: Thyroid Nodule Evaluation](https://www.mountsinai.org/care/ent/surgery/thyroid/thyroid-nodules-diseases/evaluation)  
[^4]: [Thyroid Cancer: Thyroid Nodule FNA Biopsy](https://www.thyroidcancer.com/thyroid-nodule/fna-biopsy)  
[^5]: [Thyroid.org: Thyroid Biopsy Information](https://www.thyroid.org/patient-thyroid-information/ct-for-patients/february-2023/vol-16-issue-2-p-7-8/)  
[^6]: [Thyroid.org: FNA for Thyroid Nodules](https://www.thyroid.org/fna-thyroid-nodules/)  
[^7]: [WebMD: Thyroid Biopsy Overview](https://www.webmd.com/women/thyroid-biopsy-overview)

# Common Molecular Markers Used in the United States

The following table shows the common molecular markers used in the United States for thyroid nodule evaluation, along with their sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV):

| Molecular Marker        | Sensitivity (%) | Specificity (%) | Positive Predictive Value (PPV) (%) | Negative Predictive Value (NPV) (%) |
|--------------------------|-----------------|-----------------|-------------------------------------|-------------------------------------|
| **ThyGeNEXT**           | 98[^10]        | 98[^10]        | 94[^10]                            | 99[^10]                            |
| **ThyraMIR**            | 98[^10]        | 98[^10]        | 94[^10]                            | 99[^10]                            |
| **Afirma GSC**          | 91[^8]         | 68[^8]         | 47[^8]                             | 96[^8]                             |
| **BRAF mutation**       | 85.4[^11]      | 97.1[^11]      | 91.4[^11]                          | 95.9[^11]                          |
| **ThyroSeq**            | 70[^9]         | 77[^9]         | 42[^9]                             | 91[^9]                             |
| **RAS mutation**        | 66[^12]        | 98.5[^12]      | 93.5[^12]                          | 82.5[^12]                          |
| **TERT promoter mutation** | 7[^13]       | 100[^13]       | 7[^13]                             | 97[^13]                            |

## Overview

The most commonly used molecular tests in the United States include:

1. **Afirma Genomic Sequencing Classifier (GSC)**
2. **ThyroSeq**
3. **ThyGeNEXT/ThyraMIR**
4. **BRAF mutation analysis**
5. **RAS mutation analysis**
6. **TERT promoter mutation analysis**

These tests are primarily used to evaluate indeterminate thyroid nodules (Bethesda III and IV categories) to help guide management decisions[^1][^3]. They provide more accurate risk stratification for malignancy in challenging cases.

## Clinical Considerations

- Molecular markers significantly improve diagnostic accuracy but should be interpreted alongside other clinical factors (e.g., ultrasound findings and patient risk factors)[^1].
- **ATA** and **AACE guidelines** recommend molecular testing for indeterminate nodules; however, patients should be counseled on the benefits, limitations, and uncertainties[^3].
- Molecular testing is **not recommended** when other indications for surgery are present, such as nodules >4 cm, compressive symptoms, or patient preference[^3].
- Insufficient data exists to recommend routine use of molecular testing in pediatric patients (â‰¤18 years)[^3].

---

## Citations

[^1]: [ATA: Patient Thyroid Information](https://www.thyroid.org/patient-thyroid-information/ct-for-patients/september-2022/vol-15-issue-9-p-5-6/)
[^2]: [South Carolina Blues: Molecular Markers](https://www.southcarolinablues.com/web/public/brands/medicalpolicy/external-policies/molecular-markers-in-fine-needle-aspirates-of-the-thyroid/)
[^3]: [PMC: Molecular Testing of Thyroid Nodules](https://pmc.ncbi.nlm.nih.gov/articles/PMC5915469/)
[^4]: [Allen Press: Molecular Testing Review](https://meridian.allenpress.com/aplm/article/140/12/1338/194193/Molecular-Testing-of-Thyroid-Nodules-A-Review-of)
[^5]: [PMC: Thyroid Molecular Markers](https://pmc.ncbi.nlm.nih.gov/articles/PMC6107603/)
[^6]: [PMC: Molecular Advances in Thyroid Diagnosis](https://pmc.ncbi.nlm.nih.gov/articles/PMC9999006/)
[^7]: [Endocrinology: Diagnosing Thyroid Cancer](https://www.endocrinology.org/endocrinologist/132-summer-2019/features/molecular-markers-in-diagnosing-thyroid-cancer/)
[^8]: [Afirma GSC Overview](https://scholarlycommons.libraryinfo.bhs.org/all_works/10570/)
[^9]: [ThyroSeq Details](https://pmc.ncbi.nlm.nih.gov/articles/PMC7771306/)
[^10]: [ThyGeNEXT/ThyraMIR](https://thygenext-thyramir.com)
[^11]: [BRAF Mutation Analysis](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.746776/full)
[^12]: [RAS Mutation Analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC8345070/)
[^13]: [TERT Promoter Mutation](https://erc.bioscientifica.com/view/journals/erc/21/5/825.xml)

# Limitations of Using Molecular Markers for Thyroid Nodule Diagnosis

The use of molecular markers for the diagnosis of thyroid nodules offers potential benefits but also presents several limitations. These limitations can impact their effectiveness and clinical utility in guiding management decisions for patients with indeterminate thyroid nodules.

## Limitations of Molecular Markers

### 1. Diagnostic Accuracy
- **Sensitivity and Specificity**: Many molecular tests exhibit variable sensitivity and specificity. For example, the Afirma Gene Expression Classifier (GEC) has shown sensitivity ranging from 75% to 100% and specificity from 5% to 53%, while ThyroSeq V2 displays sensitivity from 40% to 100% and specificity from 56% to 93%[^2]. Such variability can lead to uncertainty in clinical decision-making.
  
- **Low Positive Predictive Value (PPV)**: The PPV of some markers, such as RAS mutations, has been reported to be as low as 7% to 25%, indicating that a significant proportion of positive results may not correspond to malignancy[^3]. 

### 2. Overlap Between Benign and Malignant Conditions
- Many molecular markers are not exclusive to malignant conditions; they can also be present in benign nodules. This overlap complicates the interpretation of results and may lead to unnecessary surgeries or interventions for benign lesions[^1][^3].

### 3. Emerging Pathological Entities
- The introduction of new histopathological classifications, such as Non-Invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP), has further complicated the landscape. Molecular tests were developed prior to this classification and may misclassify NIFTP as malignant, thereby affecting their diagnostic performance[^3][^4].

### 4. Sampling Errors
- The accuracy of molecular testing is inherently limited by the quality of the fine needle aspiration (FNA) samples. Inadequate sampling can lead to non-diagnostic results or misclassification, which diminishes the reliability of molecular diagnostics[^1][^3].

### 5. Cost and Accessibility
- The cost-effectiveness of molecular testing remains a concern, particularly in resource-limited settings. While some studies suggest that these tests can reduce unnecessary surgeries, the actual impact on surgical decision-making has been marginal, with only a small percentage of patients experiencing altered management based on molecular testing results[^2][^4].

### 6. Lack of Long-term Outcome Data
- There is insufficient long-term data demonstrating the impact of molecular markers on patient outcomes. Most studies are limited by small sample sizes and single-institution biases, which may not reflect broader clinical practice[^3][^4].

### 7. Pediatric Considerations
- Current data do not support the routine use of molecular markers in pediatric patients due to a lack of validation studies in this population, limiting their applicability in younger patients[^2][^4].

---

In summary, while molecular markers can provide valuable information in the evaluation of thyroid nodules, their limitations must be carefully considered when interpreting results and making clinical decisions. A comprehensive approach that includes clinical history, imaging findings, and cytological analysis remains essential in managing indeterminate thyroid nodules effectively.

---

## Citations
[^1]: [PMC: Molecular Advances in Thyroid Diagnostics](https://pmc.ncbi.nlm.nih.gov/articles/PMC3603017/)  
[^2]: [PMC: Molecular Testing of Thyroid Nodules](https://pmc.ncbi.nlm.nih.gov/articles/PMC5915469/)  
[^3]: [Frontiers in Endocrinology: Molecular Markers in Thyroid Nodules](https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2020.590128/full)  
[^4]: [Johns Hopkins: Preoperative Molecular Markers in Thyroid Nodules](https://pure.johnshopkins.edu/en/publications/preoperative-molecular-markers-in-thyroid-nodules)  
[^5]: [Allen Press: Molecular Testing of Thyroid Nodules](https://meridian.allenpress.com/aplm/article/140/12/1338/194193/Molecular-Testing-of-Thyroid-Nodules-A-Review-of)  
